Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 25 minutes ago
- 2 min read
29/07/2026
AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo (Ref)
AbbVie announced that the European Commission (EC) approved RINVOQ® (upadacitinib; JAK inhibitor) for the treatment of adults and adolescents (≥12 years) with non-segmental vitiligo (NSV) who are candidates for systemic therapy.
The approval was supported by results from the Phase 3 Viti-Up clinical program (M19-044), which demonstrated significant improvements in facial and total body repigmentation compared with placebo.
The safety profile was consistent with the established safety profile of upadacitinib across approved indications.
AbbVie announced European Commission approval of RINVOQ® for severe alopecia areata (Ref)
AbbVie announced that the European Commission (EC) approved RINVOQ® (upadacitinib; JAK inhibitor) for the treatment of adults and adolescents (≥12 years) with severe alopecia areata (AA).
The approval was based on positive efficacy and safety data from the pivotal Phase 3 UP-AA clinical trials.
RINVOQ demonstrated clinically meaningful scalp hair regrowth, with a significantly higher proportion of patients achieving substantial hair regrowth compared with placebo.
The safety profile was consistent with previous experience across approved RINVOQ indications.
Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for autoimmune diseases (Ref)
Johnson & Johnson announced a strategic agreement and collaboration with Sail Biomedicines to develop in vivo CAR-T cell therapies aimed at achieving immune reset in autoimmune diseases.
The collaboration would combine Sail Biomedicines' in vivo CAR-T platform with Johnson & Johnson's expertise in CAR-T and autoimmune disease research.
The partners aimed to develop in vivo CAR-T therapies that would eliminate the need for ex vivo cell manufacturing, potentially enabling broader patient access and simpler treatment delivery.
The collaboration focused on advancing next-generation immune-reset approaches for autoimmune diseases with the goal of delivering durable clinical outcomes.
The agreement included total initial payments of $785 million (comprising a $465 million equity investment), up to $140 million in additional payments contingent on development milestones
Johnson & Johnson had been granted an exclusive option to acquire Sail Biomedicines for $2.58 billion.